In this study, we chose to evaluate the immunostimulatory capacity of the three BCG strains: Connaught, Tokyo, and Tice in vitro before evaluating different doses of BCG Tokyo over four instillations in a murine orthotopic model of bladder cancer with and without GMCSF + IFNα gene therapy. This evidence concerns the gene IFNA1 and urinary bladder cancer.